Know Labs (KNWN) 10-Q 12 Feb 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Dec. 31, 2018	Feb. 12, 2019
Document And Entity Information
Entity Registrant Name	KNOW LABS, INC.
Entity Central Index Key	1,074,828
Document Type	10-Q
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		18,107,319
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,019

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Sep. 30, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 310,779	$ 934,407
Accounts receivable, net of allowance of $60,000 and $60,000, respectively	206,084	320,538
Prepaid expenses	14,691	20,140
Inventories, net	159,223	203,582
Total current assets	690,777	1,478,667
EQUIPMENT, NET	153,690	169,333
OTHER ASSETS
Intangible assets	404,445	447,778
Other assets	7,170	7,170
TOTAL ASSETS	1,256,082	2,102,948
CURRENT LIABILITIES:
Accounts payable - trade	1,412,018	1,512,617
Accounts payable - related parties	0	12,019
Accrued expenses	71,036	72,140
Accrued expenses - related parties	676,681	657,551
Deferred revenue	0	55,959
Convertible notes payable	2,255,066	2,255,066
Notes payable - current portion of long term debt	46,576	145,186
Total current liabilities	4,461,377	4,710,538
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	0	0
Common stock - $0.001 par value, 100,000,000 shares authorized, 17,811,431 and 17,531,502 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	17,811	17,532
Additional paid in capital	32,334,605	32,163,386
Accumulated deficit	(35,560,527)	(34,791,324)
Total stockholders' deficit	(3,205,295)	(2,607,590)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,256,082	2,102,948
Series A Convertible Preferred stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	11	11
Series C Convertible Preferred stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	1,790	1,790
Series D Convertible Preferred stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	$ 1,015	$ 1,015

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
CURRENT ASSETS:
Allowance for accounts receivable	$ 60,000	$ 60,000
EQUITY (DEFICIT)
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	100,000,000	100,000,000
Common stock shares issued	17,811,431	17,531,502
Common stock shares outstanding	17,811,431	17,531,502
Series A Convertible Preferred stock [Member]
EQUITY (DEFICIT)
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	23,334	23,334
Preferred stock shares issued	20,000	20,000
Preferred stock shares outstanding	20,000	20,000
Series C Convertible Preferred stock [Member]
EQUITY (DEFICIT)
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	1,785,715	1,785,715
Preferred stock shares issued	1,785,715	1,785,715
Preferred stock shares outstanding	1,785,715	1,785,715
Series D Convertible Preferred stock [Member]
EQUITY (DEFICIT)
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	1,016,014	1,016,014
Preferred stock shares issued	1,016,014	1,016,014
Preferred stock shares outstanding	1,016,014	1,016,014

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
REVENUE	$ 602,209	$ 1,232,857
COST OF SALES	472,286	985,023
GROSS PROFIT	129,923	247,834
RESEARCH AND DEVELOPMENT EXPENSES	206,990	87,720
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	689,446	414,365
OPERATING LOSS	(766,513)	(254,251)
OTHER INCOME (EXPENSE):
Interest expense	(9,126)	(293,202)
Other income	6,436	19,188
Total other income (expense)	(2,690)	(274,014)
(LOSS) BEFORE INCOME TAXES	(769,203)	(528,265)
Income taxes - current provision	0	0
NET (LOSS)	$ (769,203)	$ (528,265)
Basic and diluted loss per common share attributable to Know Labs,, Inc. and subsidiaries common shareholders
Basic and diluted loss per share	$ (0.04)	$ (0.11)
Weighted average shares of common stock outstanding- basic and diluted	17,571,057	4,655,486

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (769,203)	$ (528,265)
Adjustments to reconcile net loss to net cash (used in) operating activities
Depreciation and amortization	61,824	13,898
Stock based compensation- stock option grants	171,499	5,187
(Loss) on sale of assets	0	(1,710)
Amortization of debt discount	0	216,774
Provision on loss on accounts receivable	1,371	0
Changes in operating assets and liabilities:
Accounts receivable	113,083	(40,117)
Prepaid expenses	5,449	(9,499)
Inventory	44,359	64,597
Other assets	0	(2,100)
Accounts payable - trade and accrued expenses	(94,593)	(90,162)
Deferred revenue	(55,959)	0
NET CASH (USED IN) OPERATING ACTIVITIES	(522,170)	(371,397)
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in equipment	(2,848)	0
Proceeds from sale of equipment	0	1,710
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES:	(2,848)	1,710
CASH FLOWS FROM FINANCING ACTIVITIES:
(Repayments) proceeds from line of credit	(98,610)	58,764
Proceeds from convertible notes payable	0	300,000
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(98,610)	358,764
NET (DECREASE) IN CASH AND CASH EQUIVALENTS	(623,628)	(10,923)
CASH AND CASH EQUIVALENTS, beginning of period	934,407	103,181
CASH AND CASH EQUIVALENTS, end of period	310,779	92,258
Supplemental disclosures of cash flow information:
Interest paid	9,126	11,723
Taxes paid	0	0
Non-cash investing and financing activities:
Benificial conversion feature	$ 0	$ 216,774

1. ORGANIZATION

1. ORGANIZATION	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
ORGANIZATION	Know Labs, Inc. (the “Company”) was incorporated under the laws of the State of Nevada in 1998. The Company has authorized 105,000,000 shares of capital stock, of which 100,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share. The Company is focused on the development, marketing and sales of a proprietary technologies which are capable of uniquely authenticating or diagnosing almost any substance or material using electromagnetic energy to create, record and detect the unique “signature” of the substance. The Company’s call these our “ChromaID™” and “Bio-RFID™” technologies. Overview Historically, the Company focused on the development of our proprietary ChromaID technology. Using light from low-cost LEDs (light emitting diodes) the Company’s map the color of substances, fluids and materials and with our proprietary processes we can authenticate, identify and diagnose based upon the color that is present. The color is both visible to us as humans but also outside of the humanly visible color spectrum in the near infra-red and near ultra-violet and beyond. The Company’s ChromaID scanner sees what we like to call “Nature’s Color Fingerprint.” Everything in nature has a unique color identifier and with ChromaID the Company can see it, and identify, authenticate and diagnose based upon the color that is present. The Company’s ChromaID scanner is capable of uniquely identifying and authenticating almost any substance or liquid using light to create, record and detect its unique color signature. The Company will continue to develop and enhance its ChromaID technology and extend its capacity. More recently, the Company has focused upon extensions and new inventions that are derived from and extend beyond our ChromaID technology. The Company’s call this technology Bio-RFID. The rapid advances made with our Bio-RFID technology in our laboratory have caused us to move quickly in to the commercialization phase of our Company as we work to create revenue generating products for the marketplace. The Company will also, as resources permit, pursue licensing opportunities with third parties who have ready applications for our technologies. In 2010, the Company acquired TransTech Systems, Inc. as an adjunct to its business. TransTech is a distributor of products for employee and personnel identification. TransTech currently provides substantially all of the Company’s revenues. The Company is in the process of commercializing its technology. To date, the Company has entered into License Agreements with Sumitomo Precision Products Co., Ltd. In addition, it has a technology license agreement with Allied Inventors, formerly Xinova and Invention Development Management Company, a subsidiary of Intellectual Ventures. The Company believes that its commercialization success is dependent upon its ability to significantly increase the number of customers that are purchasing and using its products. To date the Company has generated minimal revenue from sales of its ChromaID and Bio-RFID products. The Company is currently not profitable. Even if the Company succeeds in introducing the ChromaID and Bio-RFID technology and related products to its target markets, the Company may not be able to generate sufficient revenue to achieve or sustain profitability. ChromaID was invented by scientists under contract with the Company. Bio-RFID was invented by individuals working for the Company. The Company actively pursues a robust intellectual property strategy and has been granted twelve patents. The Company also has 20 patents pending. The Company possesses all right, title and interest to the issued patents. Ten of the pending patents are licensed exclusively to the Company in perpetuity by the Company’s strategic partner, Allied Inventors. Merger with RAAI Lighting, Inc. On April 10, 2018, the Company entered into an Agreement and Plan of Merger with 500 Union Corporation, a Delaware corporation and a wholly owned subsidiary of the Company, and RAAI Lighting, Inc., a Delaware corporation. Pursuant to the Merger Agreement, we have acquired all the outstanding shares of RAAI’s capital stock through a merger of Merger Sub with and into RAAI (the “Merger”), with RAAI surviving the Merger as a wholly owned subsidiary of the Company. Under the terms of the Merger Agreement, each share of RAAI common stock issued and outstanding immediately before the Merger (1,000 shares) were cancelled and we issued 2,000,000 shares of our common stock. As a result, we issued 2,000,000 shares of its common stock to Phillip A. Bosua, formerly the sole stockholder of RAAI. The consideration for the Merger was determined through arms-length bargaining by the Company and RAAI. The Merger was structured to qualify as a tax-free reorganization for U.S. federal income tax purposes. As a result of the Merger, the Company received certain intellectual property, related to RAAI. Appointment of Director On April 10, 2018, the Board increased the size of the Board from three to four members and Phillip A. Bosua was appointed as a member of the Board. Mr. Bosua’s term of office expires at the next annual meeting of our stockholders. On May 24, 2018, the Board of Directors increased the size of the Board from four to five members and appointed (Ret.) Admiral William Owens as a member of the Board. Admiral Owen’s term of office expires at the next annual meeting of our stockholders. Appointment of Officer On April 10, 2018, the Company appointed Mr. Bosua as Chief Executive Officer of the Company, replacing Ronald P. Erickson, who remains Chairman of the Company. Previously, Mr. Bosua served as the Company’s Chief Product Officer since August 2017. The Company entered into a Consulting Agreement with Mr. Bosua’s company, Blaze Clinical on July 7, 2017. On April 10, 2018, the Company entered into an Employment Agreement with Mr. Bosua reflecting Mr. Bosua’s appointment as Chief Executive Officer. The Employment Agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the Employment Agreement. Mr. Bosua will be paid a base salary of $225,000 per year, received 500,000 shares of common stock valued at $0.33 per share and may be entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. The Employment Agreement provides for severance pay equal to 12 months of base salary if Mr. Bosua is terminated without “cause” or voluntarily terminates his employment for “good reason.” On April 10, 2018, the Company entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019. Merger with Know Labs, Inc. On May 1, 2018, Know Labs, Inc., a Nevada corporation incorporated on April 3, 2018, and our wholly-owned subsidiary, merged with and into the Company pursuant to an Agreement and Plan of Merger dated May 1, 2018. In connection with the merger, our Articles of Incorporation were effectively amended to change our name to Know Labs, Inc. by and through the filing of Articles of Merger. This parent-subsidiary merger was approved by us, the parent, in accordance with Nevada Revised Statutes Section 92A.180. Stockholder approval was not required. This amendment was filed with the Nevada Secretary of State and became effective on May 1, 2018. Corporate Name Change and Symbol Change On May 24, 2018, the Financial Industry Regulatory Authority (“FINRA”) announced the effectiveness of a change in our name from Visualant Incorporated to Know Labs, Inc. and a change in our ticker symbol from VSUL to the new trading symbol KNWN which became effective on the opening of trading as of May 25, 2018. In addition, in connection with the name change and symbol change, we were assigned the CUSIP number of 499238103. Closing of Financing on June 25, 2018 On June 25, 2018, the Company closed a private placement and received gross proceeds of $1,750,000 in exchange for issuing 7,000,000 shares of common stock and warrants to purchase 3,500,000 shares of common stock in a private placement to accredited investors pursuant to a series of substantially identical subscription agreements. The initial exercise price of the warrants described above is $0.25 per share, subject to certain adjustments, and the warrants expire five years after their issuance. The shares and the warrants described above were issued in transactions that were not registered under the Securities Act of 1933, as amended (the “Act”) in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and/or Rule 506 of SEC Regulation D under the Act.

2. GOING CONCERN

2. GOING CONCERN	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
GOING CONCERN	The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred net losses of $769,203, $3,257,597 and $3,901,232 for the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017, respectively. Net cash used in operating activities was $522,170, $1,117,131 and $1,264,324 for the three months ended December 31, 2018 and for the years ended September 30, 2018 and 2017, respectively. The Company anticipates that it will record losses from operations for the foreseeable future. As of December 31, 2018, the Company’s accumulated deficit was $35,560,527. The Company has limited capital resources, and operations to date have been funded with the proceeds from private equity and debt financings and loans from Ronald P. Erickson, the Company’s Chief Executive Officer, or entities with which he is affiliated. These conditions raise substantial doubt about our ability to continue as a going concern. The audit report prepared by the Company’s independent registered public accounting firm relating to our financial statements for the year ended September 30, 2018 includes an explanatory paragraph expressing the substantial doubt about the Company’s ability to continue as a going concern. The Company believe that its cash on hand will be sufficient to fund our operations until February 28, 2019. We need additional financing to implement our business plan and to service our ongoing operations and pay our current debts. There can be no assurance that we will be able to secure any needed funding, or that if such funding is available, the terms or conditions would be acceptable to us. If we are unable to obtain additional financing when it is needed, we will need to restructure our operations, and divest all or a portion of our business. We may seek additional capital through a combination of private and public equity offerings, debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, and could increase our expenses and require that our assets secure such debt. Equity financing, if obtained, could result in dilution to the Company’s then-existing stockholders and/or require such stockholders to waive certain rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, the Company may be required to delay, scale back, eliminate the development of business opportunities or file for bankruptcy and our operations and financial condition may be materially adversely affected.

3. SIGNIFICANT ACCOUNTING POLIC

3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS	Basis of Presentation Principles of Consolidation Cash and Cash Equivalents Accounts Receivable and Allowance for Doubtful Accounts Inventories Equipment Long-Lived Assets Intangible Assets Research, Development and Engineering Expenses The Company’s research and development efforts are primarily focused improving the core foundational ChromaID technology and developing new and unique applications for the technology. As part of this effort, the Company typically conduct testing to ensure that ChromaID application methods are compatible with the customer’s requirements, and that they can be implemented in a cost effective manner. The Company is also actively involved in identifying new application methods. Know Lab’s team has considerable experience working with the application of light-based technologies and their application to various industries. The Company believes that its continued development of new and enhanced technologies relating to our core business is essential to its future success. The Company spent $206,990, $570,514 and $79,405 during the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017, respectively, on research and development activities. Fair Value Measurements and Financial Instruments Fair Value Measurement and Disclosures Level 1 – Quoted prices in active markets for identical assets and liabilities; Level 2 – Inputs other than level one inputs that are either directly or indirectly observable; and. Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of December 31, 2018 and September 30, 2018 are based upon the short-term nature of the assets and liabilities. Derivative Financial Instruments - Revenue Recognition Stock Based Compensation Convertible Securities Net Loss per Share As of December 31, 2017, there were options outstanding for the purchase of 15,404 common shares, warrants for the purchase of 7,767,416 common shares, 2,825,053 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock and up to 332,940 shares of the Company’s common stock issuable upon the exercise of placement agent warrants. In addition, the Company has an unknown number of shares issuable upon conversion of convertible debentures of $870,000. All of which could potentially dilute future earnings per share. Dividend Policy Use of Estimates Recent Accounting Pronouncements A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, management has not determined whether implementation of such proposed standards would be material to the Company’s consolidated financial statements.

4. ACCOUNTS RECEIVABLE_CUSTOMER

4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION	Accounts receivable were $206,084 and $320,538, net of allowance, as of December 31, 2018 and September 30, 2018, respectively. The Company had one customer in excess of 10% (12.6% and 11.3%) of the Company’s consolidated revenues for the three months ended December 31, 2018. The Company had three customers in excess of 10% (21.2%, 16.1%, and 10.7%) with accounts receivable in excess of 10% as of December 31, 2018. The Company has a total allowance for bad debt in the amount of $60,000 as of December 31, 2018.

5. INVENTORIES

5. INVENTORIES	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
INVENTORIES	Inventories were and $159,223 and $203,582 as of December 31, 2018 and September 30, 2018, respectively. Inventories consist primarily of printers and consumable supplies, including ribbons and cards, badge accessories, capture devices, and access control components held for resale. There was a $35,000 reserve for impaired inventory as of September 30, 2018 and 2017, respectively.

6. FIXED ASSETS

6. FIXED ASSETS	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
FIXED ASSETS	Fixed assets, net of accumulated depreciation, was $153,690 and $169,333 as of December 31, 2018 and September 30, 2018, respectively. Accumulated depreciation was $689,157 and $670,666 as of December 31, 2018 and September 30, 2018, respectively. Total depreciation expense was $18,491 and $13,828 for the three months ended December 31, 2018 and 2017, respectively. All equipment is used for selling, general and administrative purposes and accordingly all depreciation is classified in selling, general and administrative expenses. Property and equipment as of December 31, 2018 was comprised of the following: Estimated December 31, 2018 Useful Lives Purchased Capital Leases Total Machinery and equipment 2-10 years $ 335,154 $ 42,681 $ 377,835 Leasehold improvements 2-3 years 276,112 - 276,112 Furniture and fixtures 2-3 years 58,050 95,020 153,070 Software and websites 3- 7 years 35,830 - 35,830 Less: accumulated depreciation (551,456 ) (137,701 ) (689,157 ) $ 153,690 $ - $ 153,690

7. INTANGIBLE ASSETS

7. INTANGIBLE ASSETS	3 Months Ended
	Dec. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
INTANGIBLE ASSETS	Intangible assets as of December 31, 2018 and September 30, 2018 consisted of the following: Estimated December 31, September 30, Useful Lives 2018 2018 Technology 3 years $ 520,000 $ 520,000 Less: accumulated amortization (115,555 ) (72,222 ) Intangible assets, net $ 404,445 $ 447,778 Total amortization expense was $43,332 and $72,222 for the three months ended December 31, 2018 and the year ended December 31, 2018, respectively. Merger with RAAI Lighting, Inc. On April 10, 2018, the Company entered into an Agreement and Plan of Merger with 500 Union Corporation, a Delaware corporation and a wholly owned subsidiary of the Company, and RAAI Lighting, Inc., a Delaware corporation. Pursuant to the Merger Agreement, we have acquired all the outstanding shares of RAAI’s capital stock through a merger of Merger Sub with and into RAAI (the “Merger”), with RAAI surviving the Merger as a wholly owned subsidiary of the Company. Under the terms of the Merger Agreement, each share of RAAI common stock issued and outstanding immediately before the Merger (1,000 shares) were cancelled and converted into the right to receive 2,000 shares of the Company’s common stock. As a result, the Company issued 2,000,000 shares of its common stock to Phillip A. Bosua, formerly the sole stockholder of RAAI. The consideration for the Merger was determined through arms-length bargaining by the Company and RAAI. The Merger was structured to qualify as a tax-free reorganization for U.S. federal income tax purposes. As a result of the Merger, the Company received certain intellectual property, related to RAAI. Merger with Know Labs, Inc. On May 1, 2018, Know Labs, Inc., a Nevada corporation incorporated on April 3, 2018, and our wholly-owned subsidiary, merged with and into the Company pursuant to an Agreement and Plan of Merger dated May 1, 2018. In connection with the merger, our Articles of Incorporation were effectively amended to change our name to Know Labs, Inc. by and through the filing of Articles of Merger. This parent-subsidiary merger was approved by us, the parent, in accordance with Nevada Revised Statutes Section 92A.180. Stockholder approval was not required. This amendment was filed with the Nevada Secretary of State and became effective on May 1, 2018. RAAI had no outstanding indebtedness or assets at the closing of the Merger. The 2,000,000 shares of the Company’s common stock issued for RAAI’s shares were recorded at the fair value at the date of the merger at $520,000 and the value assigned to the patent acquired with RAAI. The fair value of the intellectual property associated with the assets acquired was $520,000 estimated by using a discounted cash flow approach based on future economic benefits. In summary, the estimate was based on a projected income approach and related discounted cash flows over five years, with applicable risk factors assigned to assumptions in the forecasted results.

8. ACCOUNTS PAYABLE

8. ACCOUNTS PAYABLE	3 Months Ended
	Dec. 31, 2018
Accounts Payable [Abstract]
ACCOUNTS PAYABLE	Accounts payable were $1,412,018 and $1,517,617 as of December 31, 2918 and September 30, 2018, respectively. Such liabilities consisted of amounts due to vendors for inventory purchases and technology development, external audit, legal and other expenses incurred by the Company. The Company had one vendor (19.8%) with accounts payable in excess of 10% of its accounts payable as of December 31, 2018. The Company does expect to have vendors with accounts payable balances of 10% of total accounts payable in the foreseeable future.

9. DERIVATIVE INSTRUMENTS

9. DERIVATIVE INSTRUMENTS	3 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS	In April 2008, the FASB issued a pronouncement that provides guidance on determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. This pronouncement was effective for financial statements issued for fiscal years beginning after December 15, 2008. The adoption of these requirements can affect the accounting for warrants and many convertible instruments with provisions that protect holders from a decline in the stock price (or “down-round” provisions). For example, warrants or conversion features with such provisions are no longer recorded in equity. Down-round provisions reduce the exercise price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise price of those instruments or issues new warrants or convertible instruments that have a lower exercise price. There was no derivative liability as of December 31, 2018 and September 30, 2018. For the year ended September 30, 2017, the Company recorded non-cash loss of $217,828 related to the “change in fair value of derivative” expense related to its derivative instruments. The Company early adopted ASU 2017-11 and has reclassified its financial instrument with down round features to equity in the amount of $410,524.

10. CONVERTIBLE NOTES PAYABLE

10. CONVERTIBLE NOTES PAYABLE	3 Months Ended
	Dec. 31, 2018
Convertible Notes Payable
CONVERTIBLE NOTES PAYABLE	Convertible notes payable as of December 31, 2018 and September 30, 2018 consisted of the following: Convertible Promissory Note dated September 30, 2016 On September 30, 2016, the Company entered into a $210,000 Convertible Promissory Note with Clayton A. Struve, an accredited investor of the Company, to fund short-term working capital. The Convertible Promissory Note accrued interest at a rate of 10% per annum and was due on March 30, 2017. The Note holder can convert the Note into common stock at $0.70 per share. During the year ended September 30, 2017, the Company recorded interest of $21,000 related to the convertible note. This note was extended in the Securities Purchase Agreement, General Security Agreement and Subordination Agreement dated August 14, 2017 with a maturity date of August 13, 2018. Also, the conversion price of the Debenture was adjusted to $0.25 per share, subject to certain adjustments. The balance was increased $75,000 during the year ended September 30, 2018. On November 16, 2018, we signed Amendment 1 to Senior Secured Convertible Redeemable Notes dated September 30, 2016 extending the due dates of the Note to February 27, 2019. On September 24, 2018, Mr. Struve converted $200,000 of the Note into 800,000 shares of our common stock. The Company recorded accrued interest of $63,493 as of December 31, 2018. Securities Purchase Agreement dated August 14, 2017 On August 14, 2017, the Company issued a senior convertible exchangeable debenture with a principal amount of $360,000 and a common stock purchase warrant to purchase 1,440,000 shares of common stock in a private placement to Clayton Struve for gross proceeds of $300,000 pursuant to a Securities Purchase Agreement dated August 14, 2017. The debenture accrues interest at 20% per annum and matures August 13, 2018. The convertible debenture contains a beneficial conversion valued at $110,629. The warrants were valued at $111,429. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest. On the same date, the Company entered into a General Security Agreement with the Mr. Struve, pursuant to which the Company has agreed to grant a security interest to the investor in substantially all of our assets, effective upon the filing of a UCC-3 termination statement to terminate the security interest held by Capital Source Business Finance Group in the assets of the Company. In addition, an entity affiliated with Ronald P. Erickson, out then Chief Executive Officer, entered into a Subordination Agreement with the investor pursuant to which all debt owed by us to such entity is subordinated to amounts owed by us to Mr. Struve under the Debenture (including amounts that become owing under any Debentures issued to the investor in the future). The initial conversion price of the Debenture is $0.25 per share, subject to certain adjustments. The initial exercise price of the Warrant is $0.25 per share, also subject to certain adjustments. As part of the Purchase Agreement, the Company granted the investor “piggyback” registration rights to register the shares of common stock issuable upon the conversion of the Debenture and the exercise of the Warrant with the Securities and Exchange Commission for resale or other disposition. The Debenture and the Warrant were issued in a transaction that was not registered under the Securities Act of 1933, as amended in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and Rule 506 of SEC Regulation D under the Act. Under the terms of the Purchase Agreement, Mr. Struve may purchase up to an aggregate of $1,000,000 principal amount of Debentures (before a 20% original issue discount) (and Warrants to purchase up to an aggregate of 250,000 shares of common stock). These securities are being offered on a “best efforts” basis by the placement agent. During the year ended September 30, 2017, $156,941 was recorded as interest expense related to debt discounts, beneficial conversions and warrants associated with Convertible Promissory Notes. On December 12, 2017, the Company closed an additional $250,000 and issued a senior convertible exchangeable debenture with a principal amount of $300,000 and a common stock purchase warrant to purchase 1,200,000 shares of common stock in a private placement dated December 12, 2017 with Mr. Struve pursuant to a Securities Purchase Agreement dated August 14, 2017. The convertible debenture contains a beneficial conversion valued at $93,174. The warrants were valued at $123,600. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest. On March 2, 2018, the Company received gross proceeds of $280,000 in exchange for issuing a senior convertible redeemable debenture with a principal amount of $336,000 and a warrant to purchase 1,344,000 shares of common stock in a private placement dated February 28, 2018 with Mr. Struve pursuant to a Securities Purchase Agreement dated August 14, 2017. The convertible debenture contains a beneficial conversion valued at $252,932. The warrants were valued at $348,096. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest. In connection with the February 28, 2018 private placement, the placement agent for the debenture and the warrant received a cash fee of $28,000 and the Company issued warrants to purchase shares of the Company’s common stock to the placement agent or its affiliates based on 10% of proceeds. On November 16, 2018, the Company signed Amendment 1 to Senior Secured Convertible Redeemable Notes dated August 14, 2017 and December 12, 2017, extending the due dates of the Notes to February 27, 2019. Convertible Redeemable Promissory Notes with Ronald P. Erickson and J3E2A2Z On March 16, 2018, the Company entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of the Company for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. The warrants were valued at $110,545. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest. The Company recorded accrued interest of $32,602 as of December 31, 2018.

11. NOTES PAYABLE, CAPITALIZED

11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT	Notes payable, capitalized leases and long-term debt as of December 31, 2018 and September 30, 2018 consisted of the following: December 31, September 30, 2018 2018 Capital Source Business Finance Group $ 46,576 $ 145,186 Total debt 46,576 145,186 Less current portion of long term debt (46,576 ) (145,186 ) Long term debt $ - $ - Capital Source Business Finance Group Know Labs, Inc. (the “Company”) finances its TransTech operations from operations and a Secured Credit Facility with Capital Source Business Finance Group. On June 15, 2018, TransTech entered into a Fifth Modification to the Loan and Security Agreement related to the $500,000 secured credit facility with Capital Source to fund its operations. The Modification extended the maturity to December 12, 2018. The secured credit facility provides for a prime rate interest floor for prime interest of 4.5% plus 2.5%. The eligible borrowing is based on 80% of eligible trade accounts receivable, not to exceed $500,000. The secured credit facility is collateralized by the assets of TransTech, with a guarantee by Know Labs, including a security interest in all assets of Know Labs. The remaining balance on the accounts receivable must be repaid by the time the secured credit facility expires on December 12, 2018, unless we renew by automatic extension for the next successive term. TransTech has $23,000 available as of December 31, 2018. On December 6, 2018, Capital Source notified TransTech that the Loan and Security Agreement and Capital Source Credit Facility would be cancelled as of March 12, 2019. Effective December 12, 2018, TransTech entered into the Sixth Modification to the Loan and Security Agreement which reduced the secured credit facility to $200,000.

12. EQUITY

12. EQUITY	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
EQUITY	Authorized Capital Stock The Company authorized 105,000,000 shares of capital stock, of which 100,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share. The Company has authorized to issue up to 100,000,000 shares of common stock with a par value of $0.001. As of December 31, 2018, we had 17,811,431 shares of common stock issued and outstanding, held by 123 shareholders of record. The number of shareholders, including beneficial owners holding shares through nominee names, is approximately 2,300. Each share of common stock entitles its holder to one vote on each matter submitted to the shareholders for a vote, and no cumulative voting for directors is permitted. Shareholders do not have any preemptive rights to acquire additional securities issued by us. As of December 31, 2018, there were options outstanding for the purchase of 2,282,668 common shares, warrants for the purchase of 15,173,398 common shares, and 4,914,071 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock. In addition, the Company has an unknown number of shares (9,020,264 common shares at the current price of $0.25 per share) are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share. Voting Preferred Stock The Company is authorized to issue up to 5,000,000 shares of preferred stock with a par value of $0.001. Series A Preferred Stock In July 2015, the Company sold Series A Preferred Stock to two investors for a total of $350,000. As of December 31, 2018, the Company had 20,000 Series A Preferred Stock issued and outstanding. Each holder of outstanding shares of Series A Preferred is entitled to the number of votes equal to the number of whole shares of common stock into which the shares of Series A Preferred held by such holder are then convertible as of the applicable record date. The Series A Preferred may not be redeemed without the consent of the holder. The Company cannot amend, alter or repeal any preferences, rights, or other terms of the Series A Preferred so as to adversely affect the Series A Preferred, without the written consent or affirmative vote of the holders of at least 66% of the then outstanding shares of Series A Preferred, voting as a separate voting group, given by written consent or by vote at a meeting called for such purpose for which notice shall have been duly given to the holders of the Series A Preferred. In connection with the issuance of the Series A Preferred, the Company also issued (i) a Series C five-year Warrant for 2 shares of common stock and (ii) a Series D five-year Warrant for 23,334 shares of common stock. The Series A Preferred Stock and Series C and D Warrants currently have no registration rights. On August 14, 2017, the price of the Series A Preferred Stock and Series C and D Warrants were adjusted to $0.25 per share pursuant to the documents governing such instruments. On September 23, 2018, a holder of Series A Preferred Stock converted 3,334 shares into 3,334 shares of common stock. In addition, the holder exercised Series C and D Warrants for 6,668 shares of common stock at $0.25 per share. Series C and D Preferred Stock and Warrants On August 5, 2016, the Company closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a yield of 8% and an ownership blocker of 4.99%. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share. To determine the effective conversion price, a portion of the proceeds received by the Company upon issuance of the Series C Preferred Stock was first allocated to the freestanding warrants issued as part of this transaction. Given that the warrants will not subsequently be measured at fair value, the Company determined that the warrants should receive an allocation of the proceeds based on their relative fair value. This is based on the understanding that the FASB staff and the SEC staff believe that a freestanding instrument issued in a basket transaction should be initially measured at fair value if it is required to be subsequently measured at fair value pursuant to US generally accepted accounting principles (“GAAP”), with the residual proceeds from the transaction allocated to any remaining instruments based on their relative fair values. As such, the warrants were allocated a fair value of approximately $514,706 upon issuance, with the remaining $735,294 of proceeds allocated to the Series C Preferred Stock. Proportionately, this allocation resulted in approximately 59% of the face amount of the Series C Preferred Stock issuance remaining, which applied to the stated conversion price of $0.70 resulted in an effective conversion price of approximately $0.41. Having determined the effective conversion price, the Company then compared this to the fair value of the underlying Common Stock as of the commitment date, which was approximately $1.06 per share, and concluded that the conversion feature did have an intrinsic value of $0.65 per share. As such, the Company concluded that the Series C Preferred Stock did contain a beneficial conversion feature and an accounting entry and additional financial statement disclosure was required. Because our preferred stock is perpetual, with no stated maturity date, and the conversions may occur any time from inception, the dividend is recognized immediately when a beneficial conversion exists at issuance. During the year ending September 30, 2016, the Company recognized preferred stock dividends of $1.16 million on Series C preferred stock related to the beneficial conversion feature arising from a common stock effective conversion rate of $0.41 versus a current market price of $1.06 per common share. On November 14, 2016, the Company issued 187,500 shares of Series D Convertible Preferred Stock and a warrant to purchase 187,500 shares of common stock in a private placement to certain accredited investors for gross proceeds of $150,000 pursuant to a Series D Preferred Stock and Warrant Purchase Agreement dated November 10, 2016. The warrants associated with the November 14, 2016 issuance were allocated a fair value of approximately $56,539 upon issuance, with the remaining $63,539 of net proceeds allocated to the Series D Preferred Stock. Proportionately, this allocation resulted in approximately 53% of the amount of the Series D Preferred Stock issuance remaining, which applied to the stated conversion price of $0.80 resulted in an effective conversion price of approximately $0.34. Having determined the effective conversion price, the Company then compared this to the fair value of the underlying Common Stock as of the commitment date, which was approximately $1.14 per share, and concluded that the conversion feature did have an intrinsic value of $0.80 per share. As such, the Company concluded that the Series D Preferred Stock did contain a beneficial conversion feature of $150,211 which was recorded as a beneficial conversion in stockholders’ equity. On December 19, 2016, the Company issued 187,500 shares of Series D Convertible Preferred Stock and a warrant to purchase 187,500 shares of common stock in a private placement to an accredited investor for gross proceeds of $150,000 pursuant to a Series D Preferred Stock and Warrant Purchase Agreement dated December 14, 2016. The warrants associated with the December 19, 2016 issuance were allocated a fair value of approximately $60,357 upon issuance, with the remaining $69,643 of net proceeds allocated to the Series D Preferred Stock. Proportionately, this allocation resulted in approximately 54% of the amount of the Series D Preferred Stock issuance remaining, which applied to the stated conversion price of $0.80 resulted in an effective conversion price of approximately $0.37. Having determined the effective conversion price, the Company then compared this to the fair value of the underlying Common Stock as of the commitment date, which was approximately $0.81 per share, and concluded that the conversion feature did have an intrinsic value of $0.44 per share. As such, the Company concluded that the Series C Preferred Stock did contain a beneficial conversion feature of $82,232 which was recorded as a beneficial conversion in stockholders’ equity. Because the Company’s preferred stock is perpetual, with no stated maturity date, and the conversions may occur any time from inception, the dividend is recognized immediately when a beneficial conversion exists at issuance. During the year ending September 30, 2017, the Company recognized preferred stock dividends of $2.3 million on Series D preferred stock related to the beneficial conversion feature arising from a common stock effective conversion rate of $0.34 and $0.37 versus the original market price of $1.14 and $1.06 per common share, respectively. On May 1, 2017, the Company issued 357,143 shares of Series D Convertible Preferred Stock and a warrant to purchase 357,143 shares of common stock in a private placement to an accredited investor for gross proceeds of $250,000 pursuant to a Series D Preferred Stock and Warrant Purchase Agreement dated May 1, 2016. The initial conversion price of the Series D Shares is $0.70 per share, subject to certain adjustments. The initial exercise price of the warrant is $0.70 per share, also subject to certain adjustments. The Company also amended and restated the Certificate of Designations, resulting in an adjustment to the conversion price of all currently outstanding Series D Shares to $0.70 per share. On August 14, 2017, the price of the Series C and D Preferred Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. After adjustment there were 3,108,356 shares of Series D preferred stock authorized. On July 17, 2018, the Company filed with the State of Nevada a second Amended and Restated Certificate of Designation of Preferences, Powers, and Rights of the Series D Convertible Preferred Stock. The Amended Certificate restates the prior Certificate of Designation filed on May 8, 2017 to decrease the number of authorized Series D shares from 3,906,250 shares to 1,016,014 shares. No other amendments were made to the preferences and rights of the Series D Convertible Preferred Stock. The filing of the Amended Certificate was unanimously approved by the Board of Directors and the shareholders of Series D Convertible Preferred Stock. Series F Preferred Stock On August 1, 2018, the Company filed with the State of Nevada a Certificate of Designation establishing the Designations, Preferences, Limitations and Relative Rights of Series F Preferred Stock (the “Designation”). The Designation authorized 500 shares of Series F Preferred Stock. The Series F Preferred Stock shall only be issued to the current Board of Directors on the date of the Designation’s filing and is not convertible into common stock. As set forth in the Designation, the Series F Preferred Stock has no rights to dividends or liquidation preference and carries rights to vote 100,000 shares of common stock per share of Series F upon a Trigger Event, as defined in the Designation. A Trigger Event includes certain unsolicited bids, tender offers, proxy contests, and significant share purchases, all as described in the Designation. Unless and until a Trigger Event, the Series F shall have no right to vote. The Series F Preferred Stock shall remain issued and outstanding until the date which is 731 days after the issuance of Series F Preferred Stock (“Explosion Date”), unless a Trigger Event occurs, in which case the Explosion Date shall be extended by 183 days. Securities Subject to Price Adjustments In the future, if we sell our common stock at a price below $0.25 per share, the exercise price of 20,000 outstanding shares of Series A Preferred Stock, 1,785,715 outstanding shares of Series C Preferred Stock, 1,016,004 outstanding shares Series D Preferred Stock that adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of a Convertible Note Payable of $2,255,066 (9,020,264 common shares at the current price of $0.25 per share) and the exercise price of additional outstanding warrants to purchase 12,714,385 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Common Stock All of the offerings and sales described below were deemed to be exempt under Rule 506 of Regulation D and/or Section 4(a)(2) of the Securities Act. No advertising or general solicitation was employed in offering the securities, the offerings and sales were made to a limited number of persons, all of whom were accredited investors and transfer was restricted by the company in accordance with the requirements of Regulation D and the Securities Act. All issuances to accredited and non-accredited investors were structured to comply with the requirements of the safe harbor afforded by Rule 506 of Regulation D, including limiting the number of non-accredited investors to no more than 35 investors who have sufficient knowledge and experience in financial and business matters to make them capable of evaluating the merits and risks of an investment in our securities. The following equity issuances occurred during the three months ended December 31, 2018: The Company issued 279,929 shares of common stock and cancelled warrants to purchase 20,071 shares of common stock at $0.25 per share to a consultant and an investor related to the cashless exercise of warrants. Warrants to Purchase Common Stock The following warrants were issued during the three months ended December 31, 2018: The Company issued 279,929 shares of common stock and cancelled warrants to purchase 20,071 shares of common stock at $0.25 per share to a consultant and an investor related to the cashless exercise of warrants. A summary of the warrants outstanding as of December 31, 2018 were as follows: December 31, 2018 Weighted Average Exercise Shares Price Outstanding at beginning of period 15,473,398 $ 0.326 Issued - - Exercised (279,929 ) (0.250 ) Forfeited - - Expired (20,071 ) (0.250 ) Outstanding at end of period 15,173,398 $ 0.328 Exerciseable at end of period 15,173,398 A summary of the status of the warrants outstanding as of December 31, 2018 is presented below: December 31, 2018 Weighted Weighted Weighted Average Average Average Number of Remaining Exercise Shares Exercise Warrants Life (In Years) Price Exerciseable Price 13,570,286 3.75 $ 0.250 13,570,286 $ 0.250 714,286 2.58 0.700 714,286 0.700 882,159 2.87 1.000 882,159 1.000 6,667 0.25 30.000 6,667 30.000 15,173,398 3.34 $ 0.328 15,173,398 $ 0.328 The significant weighted average assumptions relating to the valuation of the Company’s warrants for the three months ended December 31, 2018 were as follows: Assumptions Dividend yield 0% Expected life 1-2 years Expected volatility 125%-145% Risk free interest rate .0202-.0214% There were vested warrants of 14,284,572 as of December 31, 2018 with an aggregate intrinsic value of $9,249,235.

13. STOCK OPTIONS

13. STOCK OPTIONS	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
STOCK OPTIONS	On March 21, 2013, an amendment to the Stock Option Plan was approved by the stockholders of the Company, increasing the number of shares reserved for issuance under the Plan to 93,333 shares. Determining Fair Value under ASC 505 The Company records compensation expense associated with stock options and other equity-based compensation using the Black-Scholes-Merton option valuation model for estimating fair value of stock options granted under our plan. The Company amortizes the fair value of stock options on a ratable basis over the requisite service periods, which are generally the vesting periods. The expected life of awards granted represents the period of time that they are expected to be outstanding. The Company estimates the volatility of our common stock based on the historical volatility of its own common stock over the most recent period corresponding with the estimated expected life of the award. The Company bases the risk-free interest rate used in the Black Scholes-Merton option valuation model on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award. The Company has not paid any cash dividends on our common stock and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes-Merton option valuation model and adjusts share-based compensation for changes to the estimate of expected equity award forfeitures based on actual forfeiture experience. The effect of adjusting the forfeiture rate is recognized in the period the forfeiture estimate is changed. Stock Option Activity The Company had the following stock option transactions during the three months ended December 31, 2018: On October 31, 2018, the Board awarded stock option grants to two directors to acquire 50,000 shares each of the Company’s common stock. The grants were valued at $3.03 per share and expire on October 31, 2013. The grants vested immediately. On October 31, 2018, the Board awarded Phillip A. Bosua a stock option grant to acquire 100,000 shares of the Company’s Common stock for each $1,000,000 raised by the Company in revenue generated in a planned Kickstarter campaign. In addition, Mr. Bosua was granted a stock option grant to acquire 1,000,000 shares of the Company’s common which vests upon approval of the Company’s blood glucose measurement technology by the U.S. Food and Drug Administration. The grants were valued at $3.03 per share and expire on October 31, 2023. On October 31, 2018, the Board awarded Ronald P Erickson a stock option grant to acquire 1,000,000 shares of the Company’s common which vests upon the Company’s successful listing of its Common Stock on Nasdaq or the New York Stock Exchange (including the NYSE American Market). The grant was valued at $3.03 per share and expires on October 31, 2023. There are currently 2,282,668 options to purchase common stock at an average exercise price of $1.757 per share outstanding as of December 31, 2018 under the 2011 Stock Incentive Plan. The Company recorded $171,498 and $2,147 of compensation expense, net of related tax effects, relative to stock options for the three months ended December 31, 2018 and December 31, 2017and in accordance with ASC 505. Net loss per share (basic and diluted) associated with this expense was approximately ($0.010) and ($0.00) per share, respectively. As of December 31, 2018, there is approximately $1,697,737, net of forfeitures, of total unrecognized costs related to employee granted stock options that are not vested. These costs are expected to be recognized over a period of approximately 4.94 years. Stock option activity for the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017 was as follows: Weighted Average Options Exercise Price $ Outstanding as of September 30, 2016 50,908 $ 18.04 $ 918,627 Granted - - - Exercised - - - Forfeitures (35,504 ) (19.507 ) (692,568 ) Outstanding as of September 30, 2017 15,404 14.675 226,059 Granted 2,180,000 1.683 3,668,500 Exercised - - - Forfeitures (12,736 ) 14.764 (188,040 ) Outstanding as of September 30, 2018 2,182,668 1.698 3,706,519 Granted 100,000 3.030 303,000 Exercised - - - Forfeitures - - - Outstanding as of December 31, 2018 2,282,668 $ 1.757 $ 4,009,519 The following table summarizes information about stock options outstanding and exercisable as of December 31, 2018: Weighted Weighted Weighted Average Average Average Range of Number Remaining Life Exercise Price Number Exercise Price Exercise Prices Outstanding In Years Exerciseable Exerciseable Exerciseable 0.25 530,000 4.86 $ 0.250 66,250 $ 0.25 1.28 1,150,000 4.96 1.28 71,875 1.28 3.03 100,000 4.96 3.03 100,000 3.03 4.08-4.20 500,000 4.98 4.08-4.20 - - 13.500 1,334 0.44 13.50 1,334 13.50 15.000 1,334 - 15.00 - 15.00 2,282,668 4.94 $ 1.757 239,459 $ 1.00 There were stock option grants of 530,000 shares as of December 31, 2018 with an aggregate intrinsic value of $355,100.

14. OTHER SIGNIFICANT TRANSACTI

14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES	Related Party Transactions with Ronald P. Erickson See Notes 1, 10, 13 and 15 for related party transactions with Ronald P. Erickson. Mr. Erickson and/or entities with which he is affiliated also have accrued compensation, travel and interest of approximately $530,102 as of December 31, 2018. Related Party Transaction with Phillip A. Bosua See Notes 1, 13 and 15 for related party transactions with Phillip A. Bosua. Stock Option Grants to Directors See Note 13 for related party transactions with Directors.

15. COMMITMENTS, CONTINGENCIES

15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS	Legal Proceedings The Company may from time to time become a party to various legal proceedings arising in the ordinary course of our business. The Company is currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to our business. Employment Agreement with Phillip A. Bosua, Chief Executive Officer On April 10, 2018, the Company appointed Mr. Bosua as Chief Executive Officer of the Company, replacing Ronald P. Erickson, who remains Chairman of the Company. Mr. Erickson has been a director and officer of Know Labs since April 2003. He was appointed as our CEO and President in November 2009 and as Chairman of the Board in February 2015. Previously, Mr. Erickson was our President and Chief Executive Officer from September 2003 through August 2003 and was Chairman of the Board from August 2004 until May 2011. Phillip A. Bosua was appointed the Company’s CEO on April 10, 2018. Previously, Mr. Bosua served as the Company’s Chief Product Officer since August 2017. The Company entered into a Consulting Agreement with Mr. Bosua’s company, Blaze Clinical on July 7, 2017. From September 2012 to February 2015, Mr. Bosua was the founder and Chief Executive Officer of LIFX Inc. (where he developed and marketed an innovative “smart” light bulb) and from August 2015 until February 2016 was Vice President Consumer Products at Soraa (which markets specialty LED light bulbs). From February 2016 to July 2017, Mr. Bosua was the founder and CEO of RAAI, Inc. (where he continued the development of his smart lighting technology). From May 2008 to February 2013 he was the Founder and CEO of LimeMouse Apps, a leading developer of applications for the Apple App Store. On April 10, 2018, the Company entered into an Employment Agreement with Mr. Bosua reflecting his appointment as Chief Executive Officer. The Employment Agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the Employment Agreement. Mr. Bosua will be paid a base salary of $225,000 per year, received 500,000 shares of common stock valued at $0.33 per share and may be entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. The Employment Agreement provides for severance pay equal to 12 months of base salary if Mr. Bosua is terminated without “cause” or voluntarily terminates his employment for “good reason.” Employment Agreement with Ronald P. Erickson, Chairman of the Board and Interim Chief Financial Officer On August 4, 2017, the Board of Directors approved an Employment Agreement with Ronald P. Erickson pursuant to which the Company engaged Mr. Erickson as our Chief Executive Officer through September 30, 2018. Mr. Erickson’s annual compensation is $180,000. Mr. Erickson is also entitled to receive an annual bonus and equity awards compensation as approved by the Board. The bonus should be paid no later than 30 days following earning of the bonus. Mr. Erickson will be entitled to participate in all group employment benefits that are offered by the Company to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. If the Company terminates Mr. Erickson’s employment at any time prior to the expiration of the Term without Cause, as defined in the Employment Agreement, or if Mr. Erickson terminates his employment at any time for “Good Reason” or due to a “Disability”, Mr. Erickson will be entitled to receive (i) his Base Salary amount for one year; and (ii) medical benefits for eighteen months. On April 10, 2018, the Company entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019. Properties and Operating Leases The Company is obligated under the following non-cancelable operating leases for its various facilities and certain equipment. Years Ended December 31, Total 2019 $ 106,190 2020 72,519 2021 14,540 2022 - 2023 - Beyond - Total $ 193,249 Corporate Offices On April 13, 2017, the Company leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the net monthly payment is $2,672. The monthly payment increases approximately 3% each year and the lease expires on May 31, 2022. Lab Facilities and Executive Offices On May 1, 2018, the Company leased its lab facilities and executive offices located at 304 Alaskan Way South, Suite 102, Seattle, Washington, USA, 98101. The Company leases 2,800 square feet and the net monthly payment is $4,000. The lease expires on April 30, 2019. TransTech Facilities TransTech is located at 12142 NE Sky Lane, Suite 130, Aurora, OR 97002. TransTech leases a total of approximately 6,340 square feet of office and warehouse space for its administrative offices, product inventory and shipping operations. Effective December 1, 2017, TransTech leases this office from December 1, 2017 at $4,465 per month. The monthly payment increases approximately 3% each year and the lease expires on January 31, 2020. Until December 1, 2017, TransTech leased this office on a month to month basis at $6,942 per month.

16. SUBSEQUENT EVENTS

16. SUBSEQUENT EVENTS	3 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	The Company evaluates subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements are available. Subsequent to December 31, 2018, there were the following material transactions that require disclosure: On January 2, 2019, the Company issued 170,000 shares of restricted common stock to a Names Executive Officer and a consultant and for services during 2018. On January 16, 2019, the Company leased replacement lab facilities and executive offices located at 1517 12th Ave Suite 203 Seattle, WA 98122. The lease commences February 1, 2019 and expires June 30, 2021. The Company leases 2,642 square feet and the net monthly payment is $8,256. The monthly payment increases approximately 3% on June 30, 2019 and 2020. On January 29, 2019, the Company issued 45,888 shares of common stock and cancelled warrants to purchase 4,112 shares of common stock at $0.25 per share to an investor related to the exercise of warrants. On January 29, 2019, the Company issued 80,000 shares of common stock and cancelled 20,000 shares of Series A Convertible Preferred Stock at $0.25 per share to an investor related to the conversion of the preferred stock.

3. SIGNIFICANT ACCOUNTING POL_2

3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Policies)	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
Inventories	Inventories
Equipment	Equipment
Long-Lived Assets	Long-Lived Assets
Intangible Assets	Intangible Assets
Research, Development and Engineering Expenses	Research, Development and Engineering Expenses The Company’s research and development efforts are primarily focused improving the core foundational ChromaID technology and developing new and unique applications for the technology. As part of this effort, the Company typically conduct testing to ensure that ChromaID application methods are compatible with the customer’s requirements, and that they can be implemented in a cost effective manner. The Company is also actively involved in identifying new application methods. Know Lab’s team has considerable experience working with the application of light-based technologies and their application to various industries. The Company believes that its continued development of new and enhanced technologies relating to our core business is essential to its future success. The Company spent $206,990, $570,514 and $79,405 during the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017, respectively, on research and development activities.
Fair Value Measurements and Financial Instruments	Fair Value Measurements and Financial Instruments Fair Value Measurement and Disclosures Level 1 – Quoted prices in active markets for identical assets and liabilities; Level 2 – Inputs other than level one inputs that are either directly or indirectly observable; and. Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of December 31, 2018 and September 30, 2018 are based upon the short-term nature of the assets and liabilities.
Derivative Financial Instruments	Derivative Financial Instruments -
Revenue Recognition	Revenue Recognition
Stock Based Compensation	Stock Based Compensation
Convertible Securities	Convertible Securities
Net Loss per Share	Net Loss per Share As of December 31, 2017, there were options outstanding for the purchase of 15,404 common shares, warrants for the purchase of 7,767,416 common shares, 2,825,053 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock and up to 332,940 shares of the Company’s common stock issuable upon the exercise of placement agent warrants. In addition, the Company has an unknown number of shares issuable upon conversion of convertible debentures of $870,000. All of which could potentially dilute future earnings per share.
Dividend Policy	Dividend Policy
Use of Estimates	Use of Estimates
Recent Accounting Pronouncements	Recent Accounting Pronouncements A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, management has not determined whether implementation of such proposed standards would be material to the Company’s consolidated financial statements.

6. FIXED ASSETS (Tables)

6. FIXED ASSETS (Tables)	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Schedule of property and equipment	Estimated December 31, 2018 Useful Lives Purchased Capital Leases Total Machinery and equipment 2-10 years $ 335,154 $ 42,681 $ 377,835 Leasehold improvements 2-3 years 276,112 - 276,112 Furniture and fixtures 2-3 years 58,050 95,020 153,070 Software and websites 3- 7 years 35,830 - 35,830 Less: accumulated depreciation (551,456 ) (137,701 ) (689,157 ) $ 153,690 $ - $ 153,690

7. INTANGIBLE ASSETS (Tables)

7. INTANGIBLE ASSETS (Tables)	3 Months Ended
	Dec. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of intangible assets	Estimated December 31, September 30, Useful Lives 2018 2018 Technology 3 years $ 520,000 $ 520,000 Less: accumulated amortization (115,555 ) (72,222 ) Intangible assets, net $ 404,445 $ 447,778

11. NOTES PAYABLE, CAPITALIZE_2

11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Tables)	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Notes payable, capitalized leases and long term debt	December 31, September 30, 2018 2018 Capital Source Business Finance Group $ 46,576 $ 145,186 Total debt 46,576 145,186 Less current portion of long term debt (46,576 ) (145,186 ) Long term debt $ - $ -

12. EQUITY (Tables)

12. EQUITY (Tables)	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Summary of the warrants issued	December 31, 2018 Weighted Average Exercise Shares Price Outstanding at beginning of period 15,473,398 $ 0.326 Issued - - Exercised (279,929 ) (0.250 ) Forfeited - - Expired (20,071 ) (0.250 ) Outstanding at end of period 15,173,398 $ 0.328 Exerciseable at end of period 15,173,398
Summary of the status of the warrants outstanding	December 31, 2018 Weighted Weighted Weighted Average Average Average Number of Remaining Exercise Shares Exercise Warrants Life (In Years) Price Exerciseable Price 13,570,286 3.75 $ 0.250 13,570,286 $ 0.250 714,286 2.58 0.700 714,286 0.700 882,159 2.87 1.000 882,159 1.000 6,667 0.25 30.000 6,667 30.000 15,173,398 3.34 $ 0.328 15,173,398 $ 0.328
Weighted average assumptions relating to the valuation of the Companys warrants	Assumptions Dividend yield 0% Expected life 1-2 years Expected volatility 125%-145% Risk free interest rate .0202-.0214%

13. STOCK OPTIONS (Tables)

13. STOCK OPTIONS (Tables)	3 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stock option activity	Weighted Average Options Exercise Price $ Outstanding as of September 30, 2016 50,908 $ 18.04 $ 918,627 Granted - - - Exercised - - - Forfeitures (35,504 ) (19.507 ) (692,568 ) Outstanding as of September 30, 2017 15,404 14.675 226,059 Granted 2,180,000 1.683 3,668,500 Exercised - - - Forfeitures (12,736 ) 14.764 (188,040 ) Outstanding as of September 30, 2018 2,182,668 1.698 3,706,519 Granted 100,000 3.030 303,000 Exercised - - - Forfeitures - - - Outstanding as of December 31, 2018 2,282,668 $ 1.757 $ 4,009,519
Stock options outstanding and exercisable	Weighted Weighted Weighted Average Average Average Range of Number Remaining Life Exercise Price Number Exercise Price Exercise Prices Outstanding In Years Exerciseable Exerciseable Exerciseable 0.25 530,000 4.86 $ 0.250 66,250 $ 0.25 1.28 1,150,000 4.96 1.28 71,875 1.28 3.03 100,000 4.96 3.03 100,000 3.03 4.08-4.20 500,000 4.98 4.08-4.20 - - 13.500 1,334 0.44 13.50 1,334 13.50 15.000 1,334 - 15.00 - 15.00 2,282,668 4.94 $ 1.757 239,459 $ 1.00

15. COMMITMENTS, CONTINGENCIE_2

15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Tables)	3 Months Ended
	Dec. 31, 2018
Commitments Contingencies And Legal Proceedings
Properties and operating leases	Years Ended December 31, Total 2019 $ 106,190 2020 72,519 2021 14,540 2022 - 2023 - Beyond - Total $ 193,249

2. GOING CONCERN (Details Narra

2. GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Notes to Financial Statements
Net loss	$ (769,203)		$ (3,257,597)	$ (3,901,232)
Net cash used in operating activities	(522,170)	$ (371,397)	(1,117,131)	$ (1,264,324)
Accumulated Deficit	$ (35,560,527)		$ (34,791,324)

3. SIGNIFICANT ACCOUNTING POL_3

3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2018	Sep. 30, 2018
Reserve for impaired inventory	$ 35,000	$ 35,000
Minimum [Member]
Estimated useful lives of assets	2 years
Maximum [Member]
Estimated useful lives of assets	10 years
Leasehold Improvements [Member] | Minimum [Member]
Estimated useful lives of assets	5 years
Leasehold Improvements [Member] | Maximum [Member]
Estimated useful lives of assets	20 years

4. ACCOUNTS RECEIVABLE_CUSTOM_2

4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION (Details Narrative) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Notes to Financial Statements
Accounts receivable, net of allowance	$ 206,084	$ 320,538
Allowance for bad debt	$ 60,000

5. INVENTORIES (Details Narrati

5. INVENTORIES (Details Narrative) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Notes to Financial Statements
Inventories	$ 159,223	$ 203,582
Reserve for impaired inventory	$ 35,000	$ 35,000

6. FIXED ASSETS (Details)

6. FIXED ASSETS (Details) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Machinery and equipment (2-10 years)	$ 377,835
Leasehold improvements (5-20 years)	276,112
Furniture and fixtures (3-10 years)	153,070
Software and websites (3- 7 years)	35,830
Less: accumulated depreciation	(689,157)	$ (670,666)
Property and equipment, net	153,690	$ 169,333
Purchased [Member]
Machinery and equipment (2-10 years)	335,154
Leasehold improvements (5-20 years)	276,112
Furniture and fixtures (3-10 years)	58,050
Software and websites (3- 7 years)	35,830
Less: accumulated depreciation	(551,456)
Property and equipment, net	153,690
Capital Leases [Member]
Machinery and equipment (2-10 years)	42,681
Leasehold improvements (5-20 years)	0
Furniture and fixtures (3-10 years)	95,020
Software and websites (3- 7 years)	0
Less: accumulated depreciation	(137,701)
Property and equipment, net	$ 0

6. FIXED ASSETS (Details Narrat

6. FIXED ASSETS (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018
Notes to Financial Statements
Property and equipment, net	$ 153,690		$ 169,333
Property and equipment, accumulated depreciation	689,157		$ 670,666
Depreciation expense	$ 18,491	$ 13,828

7. INTANGIBLE ASSETS (Details)

7. INTANGIBLE ASSETS (Details) - Technology - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Intangible assets, gross	$ 520,000	$ 520,000
Less: accumulated amortization	(115,555)	(72,222)
Intangible assets, net	$ 404,445	$ 447,778

8. ACCOUNTS PAYABLE (Details Na

8. ACCOUNTS PAYABLE (Details Narrative) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Accounts Payable [Abstract]
Accounts payable - trade	$ 1,412,018	$ 1,512,617

9. DERIVATIVE INSTRUMENTS (Deta

9. DERIVATIVE INSTRUMENTS (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Change in the fair value of the liability	$ (217,828)	$ (217,828)

10. CONVERTIBLE NOTES PAYABLE (

10. CONVERTIBLE NOTES PAYABLE (Details Narrative)	Dec. 31, 2018USD ($)
Convertible Promissory Note [Member]
Accrued interest	$ 63,493
Convertible Redeemable Promissory Note [Member]
Accrued interest	$ 32,602

11. NOTES PAYABLE, CAPITALIZE_3

11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Details) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Notes Payable Capitalized Leases And Long Term Debt Details
Capital Source Business Finance Group	$ 46,576	$ 145,186
Total debt	46,576	145,186
Less current portion of long term debt	(46,576)	(145,186)
Long term debt	$ 0	$ 0

12. EQUITY (Details)

12. EQUITY (Details)	3 Months Ended
	Dec. 31, 2018$ / sharesshares
Shares
Outstanding at beginning of period	15,473,398
Issued	0
Exercised	(279,929)
Forfeited	0
Expired	(20,071)
Outstanding at end of period	15,173,398
Exercisable at end of period	15,173,398
Weighted Average Exercise Price:
Outstanding at beginning of period | $ / shares	$ .326
Issued | $ / shares	.000
Exercised | $ / shares	(.250)
Forfeited | $ / shares	.000
Expired | $ / shares	(0.250)
Outstanding at end of period | $ / shares	$ .328

12. EQUITY (Details 1)

12. EQUITY (Details 1)	3 Months Ended
	Dec. 31, 2018$ / sharesshares
Number of Warrants | shares	15,173,398
Weighted Average Remaining Life (years)	3 years 4 months 2 days
Weighted Average Exercise Price, outstanding | $ / shares	$ 0.328
Shares Exercisable | shares	15,173,398
Weighted Average Exercise Price, exerciseable | $ / shares	$ 0.328
Warrant One [Member]
Number of Warrants | shares	13,570,286
Weighted Average Remaining Life (years)	3 years 9 months
Weighted Average Exercise Price, outstanding | $ / shares	$ 0.250
Shares Exercisable | shares	13,570,286
Weighted Average Exercise Price, exerciseable | $ / shares	$ 0.250
Warrant Two [Member]
Number of Warrants | shares	714,286
Weighted Average Remaining Life (years)	2 years 6 months 29 days
Weighted Average Exercise Price, outstanding | $ / shares	$ 0.700
Shares Exercisable | shares	714,286
Weighted Average Exercise Price, exerciseable | $ / shares	$ 0.700
Warrant Three [Member]
Number of Warrants | shares	882,159
Weighted Average Remaining Life (years)	2 years 10 months 13 days
Weighted Average Exercise Price, outstanding | $ / shares	$ 1
Shares Exercisable | shares	882,159
Weighted Average Exercise Price, exerciseable | $ / shares	$ 1
Warrant Four [Member]
Number of Warrants | shares	6,667
Weighted Average Remaining Life (years)	3 months
Weighted Average Exercise Price, outstanding | $ / shares	$ 30
Shares Exercisable | shares	6,667
Weighted Average Exercise Price, exerciseable | $ / shares	$ 30

12. EQUITY (Details 2)

12. EQUITY (Details 2)	3 Months Ended
	Dec. 31, 2018
Dividend yield	0.00%
Minimum [Member]
Expected life	1 year
Expected volatility	125.00%
Risk free interest rate	0.0202%
Maximum [Member]
Expected life	2 years
Expected volatility	145.00%
Risk free interest rate	0.0214%

12. EQUITY (Details Narrative)

12. EQUITY (Details Narrative)	Dec. 31, 2018USD ($)shares
Notes to Financial Statements
Warrants Vested | shares	14,284,572
Intrinsic value | $	$ 9,249,235

13. STOCK OPTIONS (Details)

13. STOCK OPTIONS (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Sep. 30, 2017
Shares:
Outstanding at beginning of period	15,473,398
Shares granted	0
Shares exercised	279,929
Shares forfeitures	0
Outstanding at end of period	15,173,398	15,473,398
Weighted Average Exercise Price:
Outstanding at beginning of period	$ .326
Shares granted	.000
Shares exercised	.250
Shares forfeitures	(.000)
Outstanding at end of period	$ .328	$ .326
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding, End	$ 9,249,235
Stock Options
Shares:
Outstanding at beginning of period	2,182,668	15,404	50,908
Shares granted	100,000	2,180,000	0
Shares exercised	0	0	0
Shares forfeitures	0	(12,736)	(35,504)
Outstanding at end of period	2,282,668	2,182,668	15,404
Weighted Average Exercise Price:
Outstanding at beginning of period	$ 1.698	$ 14.675	$ 18.040
Shares granted	3.030	1.683	.000
Shares exercised	.000	.000	.000
Shares forfeitures	(.000)	14.764	(19.507)
Outstanding at end of period	$ 1.757	$ 1.698	$ 14.675
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding, Beginning	$ 3,706,519	$ 226,059	$ 918,627
Aggregate Intrinsic Value Outstanding, Granted	$ 303,000	$ 3,668,500	$ 0
Aggregate Intrinsic Value Outstanding, Exercised	$ 0	$ 0	$ 0
Aggregate Intrinsic Value Outstanding, Forefeitures	$ 0	$ (188,040)	$ (692,568)
Aggregate Intrinsic Value Outstanding, End	$ 4,009,519	$ 3,706,519	$ 226,059

13. STOCK OPTIONS (Details 1)

13. STOCK OPTIONS (Details 1)	3 Months Ended
	Dec. 31, 2018$ / sharesshares
Number of Outstanding Stock Options | shares	15,173,398
Weighted Average Remaining Life (years)	3 years 4 months 2 days
Weighted Average Exercise Price Exerciseable	$ 0.328
Number Exercisable | shares	15,173,398
Exercise Price 0.25
Range of Exercise Prices	$ 0.25
Number of Outstanding Stock Options | shares	530,000
Weighted Average Remaining Life (years)	4 years 10 months 10 days
Weighted Average Exercise Price Exerciseable	$ .25
Number Exercisable | shares	66,250
Weighted Average Exercise Price Exerciseable	$ .25
Exercise Price 1.28
Range of Exercise Prices	$ 1.28
Number of Outstanding Stock Options | shares	1,150,000
Weighted Average Remaining Life (years)	4 years 11 months 16 days
Weighted Average Exercise Price Exerciseable	$ 1.28
Number Exercisable | shares	71,875
Weighted Average Exercise Price Exerciseable	$ 1.28
Exercise Price 3.03
Range of Exercise Prices	$ 3.03
Number of Outstanding Stock Options | shares	100,000
Weighted Average Remaining Life (years)	4 years 11 months 16 days
Weighted Average Exercise Price Exerciseable	$ 3.03
Number Exercisable | shares	100,000
Weighted Average Exercise Price Exerciseable	$ 3.03
Exercise Price 4.08-4.20
Number of Outstanding Stock Options | shares	500,000
Weighted Average Remaining Life (years)	4 years 11 months 23 days
Number Exercisable | shares	0
Weighted Average Exercise Price Exerciseable	$ 0
Exercise Price 4.08-4.20 | Minimum [Member]
Range of Exercise Prices	4.08
Weighted Average Exercise Price Exerciseable	4.08
Exercise Price 4.08-4.20 | Maximum [Member]
Range of Exercise Prices	4.20
Weighted Average Exercise Price Exerciseable	4.20
Exercise Price 13.500
Range of Exercise Prices	$ 13.500
Number of Outstanding Stock Options | shares	1,334
Weighted Average Remaining Life (years)	5 months 8 days
Weighted Average Exercise Price Exerciseable	$ 13.50
Number Exercisable | shares	1,334
Weighted Average Exercise Price Exerciseable	$ 13.50
Exercise Price 15.000
Range of Exercise Prices	$ 15
Number of Outstanding Stock Options | shares	1,334
Weighted Average Exercise Price Exerciseable	$ 15
Number Exercisable | shares	0
Weighted Average Exercise Price Exerciseable	$ 15
Exercise Price Total
Number of Outstanding Stock Options | shares	2,282,668
Weighted Average Remaining Life (years)	4 years 11 months 8 days
Weighted Average Exercise Price Exerciseable	$ 1.757
Number Exercisable | shares	239,459
Weighted Average Exercise Price Exerciseable	$ 1

13. STOCK OPTIONS (Details Narr

13. STOCK OPTIONS (Details Narrative)	3 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Options to purchase common stock under 2011 Stock Incentive Plan	15,173,398
Average exercise price under 2011 Stock Incentive Plan | $ / shares	$ 0.328
Compensation expense | $	$ 171,498
Unrecognized compensation costs | $	$ 1,697,737
Period for recognition	4 years 11 months 8 days
Exercisable at end of period	15,173,398
Stock options granted	0
Aggregate intrinsic value | $	$ 355,100
2011 Stock Incentive Plan
Options to purchase common stock under 2011 Stock Incentive Plan	2,282,668
Average exercise price under 2011 Stock Incentive Plan | $ / shares	$ 1.757

14. OTHER SIGNIFICANT TRANSAC_2

14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details narrative)	3 Months Ended
	Dec. 31, 2018USD ($)
Chief Executive Officer
Accrued liabilities related parties from advances	$ 530,102

15. COMMITMENTS, CONTINGENCIE_3

15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Details)	Dec. 31, 2018USD ($)
Commitments Contingencies And Legal Proceedings Details Abstract
2,019	$ 106,190
2,020	72,519
2,021	14,540
2,022	0
2,023	0
Beyond	0
Total	$ 193,249